Literature DB >> 21411201

Chronic thrombotic microangiopathy secondary to chemotherapy for urothelial carcinoma in a patient with a history of Wegener granulomatosis.

Jacob G Thomas1, Sanjeev Sethi, Suzanne M Norby.   

Abstract

We present the case of a 62-year-old man with a history of Wegener granulomatosis who developed chronic thrombotic microangiopathy attributed to gemcitabine chemotherapy. Wegener granulomatosis had been diagnosed 15 years earlier, and the patient was treated using cyclophosphamide and prednisone, then maintained on mycophenolate mofetil and prednisone. Four years previously, he had been treated with mitomycin C for urothelial carcinoma and at the time of presentation had developed significant anemia and thrombocytopenia after a course of gemcitabine and carboplatin due to metastasis of the carcinoma. He was managed using red blood cell and platelet transfusions but then developed acute kidney injury, along with progressive dyspnea and pulmonary infiltrates. Imaging studies showed bilateral ureteral obstruction requiring placement of nephrostomy tubes. Because of concern about a flare of Wegener granulomatosis after withdrawing maintenance immunosuppression in the context of the malignancy, a kidney biopsy was performed that showed chronic thrombotic microangiopathy, likely secondary to gemcitabine chemotherapy. Clinical, laboratory, and pathologic findings of this case are discussed to illustrate the natural history of thrombotic microangiopathy associated with gemcitabine chemotherapy.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411201     DOI: 10.1053/j.ajkd.2011.01.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

1.  Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

Authors:  Florence Daviet; Franck Rouby; Pascale Poullin; Julie Moussi-Francès; Marion Sallée; Stéphane Burtey; Julien Mancini; Florence Duffaud; Renaud Sabatier; Bertrand Pourroy; Aurélie Grandvuillemin; Steven Grange; Véronique Frémeaux-Bacchi; Paul Coppo; Joëlle Micallef; Noémie Jourde-Chiche
Journal:  Br J Clin Pharmacol       Date:  2018-12-18       Impact factor: 4.335

2.  Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect.

Authors:  Toby A Eyre; Sarah Gooding; Ishita Patel; Niall Moore; Chris Hatton; Graham P Collins
Journal:  Int J Hematol       Date:  2014-03-02       Impact factor: 2.490

3.  Gemcitabine-Induced Hemolytic Uremic Syndrome in Lung Cancer: A Case Report.

Authors:  Prashant Ahlawat; Monica Gupta; Prateek Upadhyay; Shivani Gupta; Amanjot Kaur
Journal:  Cureus       Date:  2022-01-04

4.  A case of gemcitabine-induced thrombotic microangiopathy in a urothelial tumor patient with a single kidney.

Authors:  Hyunjin Ryu; Eunjeong Kang; Seokwoo Park; Sehoon Park; Kyoungbun Lee; Kwon Wook Joo; Hajeong Lee
Journal:  Kidney Res Clin Pract       Date:  2015-07-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.